Nippon India Nifty Pharma ETF
NAV
₹27.3
as of 6 Oct 2026
Nippon India Nifty Pharma ETF is an open-ended Other ETFs scheme from Nippon India Mutual Fund managing ₹1,761 crore (as of 31 Aug 2026). Its Direct-plan NAV is ₹27.3 as of 6 Oct 2026. The expense ratio is 0.24% a year. Managed by Jitendra Tolani. This page is factual data only – it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.24% / yr
- as of 31 Aug 2026
- Fund size
- ₹1,761 crore
- as of 31 Aug 2026
- SIP available
- No
- Launched
- 6 Jul 2021
- ISIN
- INF204KC1089
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from nyvo’s own NAV data.
Rebased to 100data to 5 Oct 2026Benchmark: NIFTY Pharma
Nippon India Nifty Pharma ETF
₹185
+85% on ₹100 over 5.0 yrs
Other ETFs average
₹159
+59% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 1.83% | -1.84% | +3.67 |
| 6 months | 19.03% | 15.24% | +3.79 |
| 1 year | 20.34% | 13.84% | +6.50 |
| 3 years (CAGR) | 20.47% | 19.84% | +0.63 |
| 5 years (CAGR) | 12.69% | 13.03% | -0.34 |
No category average is available for this fund. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible – read that number first.
1-year holding periods
- Worst
- -10.8%
- Median
- 13.8%
- Best
- 60.8%
49 windows over the last 60 months, stepped monthly; 76% ended positive. Worst window began 3 Jan 2022. Windows overlap – this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 15.8%
- Median
- 20.6%
- Best
- 25.5%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 1 Apr 2022. Windows overlap – this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.95
- Sharpe ratio (5Y)
- 0.56
- Sortino ratio (3Y)
- 1.62 vs category 1.63
- Standard deviation (3Y)
- 15.98%
- Beta (3Y)
- 0.94
- Alpha (3Y)
- 0.41%
- Deepest fall (5Y)
- -18.05%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high – how deep and for how long is what a drawdown feels like.
Deepest fall
-15.2%
Right now
-4.0% below peak
Ahead of its benchmark in 39% of months (window: 3y, monthly) – benchmark: NIFTY Pharma, name shown only.
Where the money actually is
Equity
99.9%
Cash
0.1%
Whole-portfolio split, as of 31 Aug 2026. The size split below covers only the equity slice of this.
What it owns
24 positions · top 10 = 78.8%
Market-cap mix (equity sleeve)
Large 47.8%Mid 45.0%Small 7.1%Other 0.1%
as of 31 Aug 2026
Holdings by sector
Healthcare(10 in top 10)99.9%
- Sun Pharmaceuticals Industries Ltd20.75%
- Divi's Laboratories Ltd11.88%
- Cipla Ltd7.83%
- Laurus Labs Ltd7.36%
- Torrent Pharmaceuticals Ltd7.34%
- Dr Reddy's Laboratories Ltd6.95%
- Lupin Ltd5.25%
- Aurobindo Pharma Ltd4.69%
- Glenmark Pharmaceuticals Ltd3.69%
- Alkem Laboratories Ltd3.08%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Aug 2026. Portfolio turnover 46.4% vs category 38.4% a year.
Money in, money out
- Net flow, 12 months
- +₹437 cr
- Net flow, 3 months
- +₹4 cr
as of 31 Aug 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of Nippon India Nifty Pharma ETF?
- ₹27.3 per unit as of 6 Oct 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of Nippon India Nifty Pharma ETF?
- 0.24% a year for the Direct plan, as of 31 Aug 2026.
- How large is Nippon India Nifty Pharma ETF?
- ₹1,761 crore under management as of 31 Aug 2026, in the Other ETFs category.
- How risky is Nippon India Nifty Pharma ETF?
- Its SEBI Riskometer reading is "Very High Risk".
- What are the 5-year returns of Nippon India Nifty Pharma ETF?
- 12.69% a year over the last 5 years (Direct plan, CAGR), against a Other ETFs average of 13.03%. Past returns do not predict future returns.
- What is the worst 3-year return of Nippon India Nifty Pharma ETF?
- 15.8% a year – the weakest of 25 overlapping 3-year holding periods, beginning 1 Apr 2022. The median was 20.6% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages Nippon India Nifty Pharma ETF?
- Jitendra Tolani, managing this fund for 1.6 years.
Where this fund sits
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund – growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Other ETFs funds
Data: nyvo research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (NIFTY Pharma) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.